New cannabis-infused lozenges provide Texas patients with convenient sublingual doses of THC and CBD for conditions such as terminal cancer, spasticity, autism, epilepsy, and incurable neurological diseases

AUSTIN, TexasSept. 22, 2020 /PRNewswire/ — Surterra Texas, a division of the privately-held, multi-state, cannabis company Parallel and a leading medical cannabis company in the Texas market, today announced the availability of the first cannabis-infused lozenges for patients in the state of Texas. This introduction of lozenges, in addition to the currently available tinctures, is the second new product offering by Surterra Texas in the past two months.

Surterra Texas Cannabis Infused Lozenges
Surterra Texas Cannabis Infused Lozenges

Surterra Texas’ lozenges are being introduced in two product brand lines:  Soothe™ Watermelon Lozenges with a 1:1 ratio of CBD:THC (2.5mg CBD and 2.5mg THC per lozenge) and Relief™ Watermelon Lozenges with a 1:9 ratio of CBD:THC (0.5mg CBD and 4.5mg THC per lozenge). Each child-resistant package of lozenges contains 20 lozenges and will be available for $30 per package.

“We are excited that Surterra Texas is the first medical cannabis provider to offer cannabis-infused lozenges to patients in Texas,” said Marcus Ruark, President of Surterra Texas. “Our latest product offering reflects Surterra’s commitment to continuous product innovation, a wide variety of products to choose from, and the development of advanced, high-quality, natural cannabis remedies for Texans.”

In addition to offering medical cannabis lozenges in Texas, Surterra Texas continues to offer a range of medical cannabis tinctures, including TranquilTM, containing a 19:1 CBD:THC ratio; SereneTM, containing a 4:1 CBD:THC ratio; and SootheTM, containing a 1:1 CBD:THC ratio. Each tincture blend has been formulated with proprietary targeted terpene profiles to enhance the experience of the cannabinoid ratios and to help patients with approved treatable conditions under the Texas Compassionate Use Program, including terminal….

More at.